Skip to main content

Table 3 Surface under the cumulative ranking curve (SUCRA) data for six outcomes

From: Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis

Treatment Surface Under the Cumulative Ranking Curve (SUCRA)
MMR within 12 months CCyR within 12 months Progression to AP-CML Overall Discontinuation Discontinuation for Drug-related AEs Serious AEs
Bosutinib 400 mg qd 0.428 0.684 0.259 0.318 0.346 0.572
Bosutinib 500 mg qd 0.570 0.416 0.872 0.520 0.719 0.581
Dasatinib 100 mg qd 0.624 0.736 0.302 0.337 0.312 0.632
IFN + Ara-C 0.000 0.000 0.719 0.726 0.476
Imatinib 400 mg qd 0.209 0.335 0.406 0.383 0.158 0.481
Imatinib 400 mg qd + Ara-C 0.172 0.340 0.482 0.903 0.769 0.483
Imatinib 400 mg qd + IFN 0.321 0.411 0.350 0.653 0.958 0.488
Imatinib 400 mg qd after IFN 0.071 0.076 0.159
Imatinib 600 mg qd 0.449 0.311 0.254 0.352 0.187 0.477
Imatinib 800 mg qd 0.682 0.730 0.388 0.525 0.576 0.528
Nilotinib 300 mg bid 0.791 0.759 0.301 0.372 0.234 0.543
Nilotinib 400 mg bid 0.839 0.781 0.293 0.416 0.440 0.556
Ponatinib 45 mg qd 0.997 0.419 0.649 0.837
Radotinib 300 mg bid 0.750 0.895 0.283 0.343
Radotinib 400 mg bid 0.596 0.538 0.561 0.688
  1. (“-” means “can’t be evaluated”)